We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States.... Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is SRK-015 which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Show more
- Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3rd, at 1:50 p.m CDT/2:50 p.m. EDT - Company will host conference call to discuss the...
Phase 2 EMBRAZE proof-of-concept trial designed to assess apitegromab's ability to safely preserve lean muscle mass in individuals on GLP-1 receptor agonist therapy for obesity New preclinical...
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious...
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other...
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.08 | -16.7471819646 | 12.42 | 12.83 | 10.31 | 933379 | 11.358744 | CS |
4 | -4.36 | -29.6598639456 | 14.7 | 15.825 | 10.31 | 840920 | 13.39007354 | CS |
12 | -5.38 | -34.2239185751 | 15.72 | 17.9 | 10.31 | 905390 | 14.76627453 | CS |
26 | -1.63 | -13.6173767753 | 11.97 | 21.17 | 10.31 | 888116 | 15.83405153 | CS |
52 | 3.99 | 62.8346456693 | 6.35 | 21.17 | 5.56 | 708635 | 13.03730992 | CS |
156 | -16.69 | -61.7462079171 | 27.03 | 44.95 | 4.325 | 499898 | 12.47152531 | CS |
260 | -9.22 | -47.1370143149 | 19.56 | 70 | 4.325 | 460192 | 20.10956632 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions